The FDA has recently updated the “Purple Book” — a database containing information about all licensed biological products — new additions include patent information relating to biologics as well as FDA regulatory exclusivity information.
According to Pharmaceutical Online, the directory provides the opportunity for:
(i) potential partnerships for licensing of existing intellectual property;
(ii) new strategies regarding intellectual property enforcement and protection; and, potentially,
(iii) opportunities for the development of new technology.
Here is the link: https://purplebooksearch.fda.gov/
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources